Latest news with #Brukinsa
&w=3840&q=100)
Business Standard
10-06-2025
- Business
- Business Standard
Glenmark Pharma rises 2% as company to launch blood cancer treatment drug
Glenmark Pharma share price rose 1.7 per cent in trade on Tuesday, June 10, 2025, logging an intraday high at ₹1,626.6 per share on BSE. At 10:30 AM, Glenmark Pharma shares were trading 1.56 per cent higher at ₹1,623.35 per share on the BSE. In comparison, the BSE Sensex was up 0.05 per cent at 82,482.52. The company's market capitalisation stood at ₹45,811.07 crore. Its 52-week high was at ₹1,830.05 per share and 52-week low was at ₹1,176 per share. In the past one year, Glenmark shares have gained 33 per cent as compared to Sensex's rise of around 8 per cent. What is boosting rally in Glenmark Pharma shares? The stock gained after the company announced the upcoming launch of zanubrutinib, under the brand name Brukinsa in India. Brukinsa, developed by global oncology company BeOne Medicines (formerly BeiGene), is an orally available Bruton's tyrosine kinase (BTK) inhibitor designed to treat multiple types of B-cell blood cancers. It is the first and only BTK inhibitor approved in India for five types of B-cell malignancies. According to the filing, Brukinsa has already been approved in more than 70 countries, with clinical efficacy demonstrated through trials such as ALPINE, ASPEN and SEQUOIA. Its entry into the Indian market addresses a critical need for new and effective blood cancer treatments. The drug offers a unique pharmacological profile with high response rates and durable disease control across multiple B-cell malignancies. It allows a flexible dosing schedule—once or twice daily—tailored to patient needs. In the ALPINE trial for relapsed or refractory chronic lymphocytic leukaemia (CLL), Brukinsa showed a lower incidence of serious cardiac side effects compared to ibrutinib, a widely used targeted therapy. Fewer patients discontinued Brukinsa due to heart-related complications. About Glenmark Pharmaceuticals Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. About BeOne Medicines BeOne Medicines, formerly known as BeiGene, is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide.
News18
10-06-2025
- Business
- News18
Stocks To Watch: Wipro, Tata Power, Jana SFB, Tech Mahindra, Zomato, And Others
Last Updated: Stocks to watch: Shares of firms like Wipro, Tata Power, Jana SFB, Tech Mahindra, Zomato, and others will be in focus on Tuesday's trade Stocks to Watch on June 10, 2025: Markets started the week on a strong footing, extending Friday's rally and gaining nearly half a percent. In today's session, stocks like Wipro, Motilal Oswal, Jana Small Finance Bank (SFB), Force Motors, and Tech Mahindra will be in focus amid key developments. Wipro Promoter entity Azim Premji Trust has sold 20.23 crore shares of Wipro worth Rs 5,057 crore through a block deal. Motilal Oswal The Securities and Exchange Board of India (SEBI) has imposed a Rs 3 lakh fine on Motilal Oswal Financial Services (MOFSL) for regulatory violations. Tech Mahindra Lakshmanan Chidambaram, President of Tech Mahindra Americas' strategic vertical business, has announced his retirement effective June 30. Zomato Parent company Eternal has introduced a new long-distance fee for restaurant partners on orders beyond 4 km, aimed at enhancing profitability and improving delivery partner payouts. Tata Power Tata Power announced that its subsidiary, TP Solar, has surpassed 4 GW of solar module output at its Tamil Nadu plant, producing a cumulative 4,049 MW of solar modules and 1,441 MW of solar cells as of May 31, 2025. Zee Entertainment has entered into a strategic equity partnership with start-up Bullet, co-founded by Azim Lalani and Saurabh Kushwah. This marks Zee's first investment since its shift to a content and technology company. Glenmark Pharmaceuticals Glenmark is preparing to launch Zanubrutinib, branded as 'Brukinsa,' in India after receiving approval from the Drugs Controller General of India (DCGI). The drug is a significant advancement in treating certain blood cancers. Mahindra & Mahindra Mahindra & Mahindra has increased its stake in Mahindra & Mahindra Financial Services (MMFSL) through the allotment of shares in MMFSL's rights issue. Jana Small Finance Bank Jana SFB has filed an application with the Reserve Bank of India (RBI) to transition from a small finance bank to a universal bank, in line with RBI's licensing guidelines. Vishnu Prakash R Punglia (VPRPL) CARE Ratings has downgraded VPRPL's ratings and outlook on its short and long-term bank facilities, revising the long-term rating to CARE BBB with a negative outlook from CARE BBB+ with a stable outlook. Disclaimer:Disclaimer: The views and investment tips by experts in this report are their own and not those of the website or its management. Users are advised to check with certified experts before taking any investment decisions. First Published: June 10, 2025, 07:41 IST
&w=3840&q=100)
Business Standard
09-06-2025
- Business
- Business Standard
Glenmark set to launch blood cancer treatment drug Brukinsa in India
Glenmark Pharmaceuticals Ltd, a global pharmaceutical company, is set to introduce zanubrutinib in India under the brand name Brukinsa, following approval from the Drugs Controller General of India (DCGI). Brukinsa, developed by global oncology company BeOne Medicines (formerly BeiGene), is an orally available Bruton's tyrosine kinase (BTK) inhibitor designed to treat multiple types of B-cell blood cancers. It is the first and only BTK inhibitor approved in India for five types of B-cell malignancies. Approved in over 70 countries Brukinsa has already been approved in more than 70 countries, with clinical efficacy demonstrated through trials such as ALPINE, ASPEN and SEQUOIA. Its entry into the Indian market addresses a critical need for new and effective blood cancer treatments. The drug offers a unique pharmacological profile with high response rates and durable disease control across multiple B-cell malignancies. It allows a flexible dosing schedule—once or twice daily—tailored to patient needs. In the ALPINE trial for relapsed or refractory chronic lymphocytic leukaemia (CLL), Brukinsa showed a lower incidence of serious cardiac side effects compared to ibrutinib, a widely used targeted therapy. Fewer patients discontinued Brukinsa due to heart-related complications. "We look forward to bringing Brukinsa to India in the coming months as part of our ongoing partnership with BeiGene (now BeOne Medicines)," said Alok Malik, President and Business Head – India Formulations, Glenmark Pharmaceuticals. 'This launch marks a significant milestone in our innovative oncology portfolio, offering patients in India access to a globally trusted therapy with proven efficacy and safety. It underscores Glenmark's ongoing commitment to providing effective and advanced treatments for patients with haematological malignancies," he added. Global partnership expands to India Adam Roach, Senior Vice President and Head of the Japan and Asia Pacific region at BeiGene, commented: 'The introduction of Brukinsa in India marks an important step in our ongoing mission to expand patient access to innovative oncology treatments across the Asia Pacific region.' 'We are proud to support Glenmark in bringing this therapy to patients in India, furthering our shared commitment to improve healthcare outcomes globally,' he said.
Mint
09-06-2025
- Business
- Mint
Glenmark to launch cancer drug Zanubrutinib in India
New Delhi: Glenmark Pharmaceuticals on Monday said it will launch cancer treatment drug zanubrutinib in India following approval by the Drugs Controller General of India (DCGI). Zanubrutinib will be marketed in India under the brand name Brukinsa. It is the first and only Bruton's tyrosine kinase (BTK) inhibitor approved in India for the treatment of five distinct B-cell malignancies: chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, and follicular lymphoma. "We look forward to bringing Brukinsa to India in the coming months as part of our ongoing partnership with BeiGene (now BeOne Medicines)," Glenmark Pharmaceuticals President and Business Head - India Formulations Alok Malik said. The launch marks a significant milestone in our innovative oncology portfolio, offering patients in India access to a globally trusted therapy with proven efficacy and safety, he added. Glenmark shares on Monday ended 0.68 per cent up at ₹ 1,600.85 apiece on BSE. In March, Glenmark Pharmaceuticals had launched a medication for glycemic control and weight-loss for diabetes patients. The Mumbai-based drug firm launched Empagliflozin, a widely recognised SGLT2 inhibitor, under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)''Glempa-L (Empagliflozin 10/25 mg Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg Metformin 500/1000 mg). The medications are designed to improve glycemic control in adults with type 2 diabetes mellitus while also reducing cardiovascular outcomes in patients with cardiovascular risk. Studies have demonstrated several benefits of Empagliflozin, including effectively improving glycemic control, supporting weight-loss, and reducing cardiovascular-renal risks in patients with type 2 diabetes mellitus. Empagliflozin has also demonstrated benefits in heart failure patients by lowering the cardiovascular death or hospitalisation. "The launch of Glempa range reinforces this commitment by providing a comprehensive and affordable solution that empowers healthcare professionals and patients to manage type 2 diabetes mellitus with established cardiovascular disease more effectively," Glenmark Pharmaceuticals President and Head of India Formulations Business Alok Malik had said.
Time of India
09-06-2025
- Business
- Time of India
Glenmark to launch DCGI-approved cancer drug in India
Glenmark Pharmaceuticals on Monday said it will launch cancer treatment drug zanubrutinib in India following approval by the Drugs Controller General of India ( DCGI ). Zanubrutinib will be marketed in India under the brand name Brukinsa . It is the first and only Bruton's tyrosine kinase (BTK) inhibitor approved in India for the treatment of five distinct B-cell malignancies: chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, and follicular lymphoma. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Bank Owned Properties For Sale In Larantuka (Prices May Surprise You) Foreclosed Homes | Search ads Search Now Undo "We look forward to bringing Brukinsa to India in the coming months as part of our ongoing partnership with BeiGene (now BeOne Medicines)," Glenmark Pharmaceuticals President and Business Head - India Formulations Alok Malik said. The launch marks a significant milestone in our innovative oncology portfolio, offering patients in India access to a globally trusted therapy with proven efficacy and safety, he added. Glenmark shares on Monday ended 0.68 per cent up at Rs 1,600.85 apiece on BSE.
